AR114148A2 - Composición terapéutica saborizada basada en arcilla - Google Patents

Composición terapéutica saborizada basada en arcilla

Info

Publication number
AR114148A2
AR114148A2 ARP180103440A ARP180103440A AR114148A2 AR 114148 A2 AR114148 A2 AR 114148A2 AR P180103440 A ARP180103440 A AR P180103440A AR P180103440 A ARP180103440 A AR P180103440A AR 114148 A2 AR114148 A2 AR 114148A2
Authority
AR
Argentina
Prior art keywords
clay
therapeutic composition
based flavored
flavored therapeutic
flavor
Prior art date
Application number
ARP180103440A
Other languages
English (en)
Inventor
Hazif Denis Le
Jrme Barra
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of AR114148A2 publication Critical patent/AR114148A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/12—Magnesium silicate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Confectionery (AREA)

Abstract

Composición terapéutica saborizada que contiene una arcilla como principio activo, y caracterizada porque la arcilla es una esmectita dioctaédrica y el sabor está encapsulado.
ARP180103440A 2007-08-13 2018-11-23 Composición terapéutica saborizada basada en arcilla AR114148A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07291005A EP2025332A1 (fr) 2007-08-13 2007-08-13 Composition thérapeutique aromatisée à base d'argile

Publications (1)

Publication Number Publication Date
AR114148A2 true AR114148A2 (es) 2020-07-29

Family

ID=39052728

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080103533A AR067929A1 (es) 2007-08-13 2008-08-13 Composicion terapeutica saborizada basada en arcilla
ARP180103440A AR114148A2 (es) 2007-08-13 2018-11-23 Composición terapéutica saborizada basada en arcilla

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP080103533A AR067929A1 (es) 2007-08-13 2008-08-13 Composicion terapeutica saborizada basada en arcilla

Country Status (27)

Country Link
US (2) US20100159013A1 (es)
EP (3) EP2025332A1 (es)
JP (2) JP5670189B2 (es)
KR (2) KR20140133617A (es)
CN (2) CN104173371A (es)
AR (2) AR067929A1 (es)
BR (1) BRPI0814979A2 (es)
CA (1) CA2696062C (es)
CL (1) CL2008002366A1 (es)
DK (1) DK2194968T3 (es)
EA (1) EA017118B1 (es)
ES (2) ES2421379T3 (es)
GE (1) GEP20125539B (es)
HK (2) HK1143956A1 (es)
HU (1) HUE029713T2 (es)
MA (1) MA31678B1 (es)
ME (1) ME00975B (es)
MX (1) MX2010001533A (es)
NO (1) NO20100114L (es)
PE (1) PE20090939A1 (es)
PL (2) PL2710998T3 (es)
PT (2) PT2194968E (es)
SA (1) SA08290496B1 (es)
TN (1) TN2010000058A1 (es)
TW (2) TWI519303B (es)
UA (1) UA97408C2 (es)
WO (1) WO2009056703A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025332A1 (fr) * 2007-08-13 2009-02-18 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Composition thérapeutique aromatisée à base d'argile
FR2952814B1 (fr) * 2009-11-23 2013-07-19 Ephyla Sas Composition comprenant un complexe de phyllosilicates organiquement modifies generer des emulsions huile dans eau eventuellement a froid
BR112013017875B1 (pt) 2011-01-12 2021-06-29 Sooft Italia Spa Composição oftálmica
ITUA20162277A1 (it) * 2016-04-04 2017-10-04 Chemists Res Srl Composizione comprendente diosmectite
CN105902625A (zh) * 2016-05-26 2016-08-31 朱胜利 一种小儿止泻药的服用方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707367A (en) * 1984-07-16 1987-11-17 Sunkist Growers, Inc. Solid essential oil flavor composition
AU4635285A (en) 1984-07-16 1986-02-10 Sunkist Growers, Inc. Solid essential oil flavor composition and method of manufacture
JPH064530B2 (ja) * 1985-02-23 1994-01-19 日本化薬株式会社 親水性基剤
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
EP0693884A4 (en) * 1993-04-16 1996-03-27 Mccormick & Co Inc ENCLOSURE COMPOSITIONS
FR2770778B1 (fr) * 1997-11-12 2000-05-26 Investigations Therapeutiques Composition pour le traitement des gastro-enterites aigues, procede de fabrication de cette composition et solution de traitement obtenue a partir de cette composition
KR20030050958A (ko) * 2001-12-20 2003-06-25 송우영 디옥타헤드랄 스멕타이트를 유효성분으로 함유하는 항균성외용조성물
US8334007B2 (en) * 2003-03-19 2012-12-18 Firmenich Sa Continuous process for the incorporation of a flavor or fragrance ingredient or composition into a carbohydrate matrix
CN100340235C (zh) * 2004-05-21 2007-10-03 山东绿叶制药有限公司 蒙脱石分散片及其制备工艺
EP1627573A1 (en) * 2004-08-20 2006-02-22 Firmenich Sa A process for the incorporation of a flavor or fragrance ingredient or composition into a carbohydrate matrix
JP2006083071A (ja) * 2004-09-14 2006-03-30 Takasago Internatl Corp 香粧品用固形製剤
WO2007051427A1 (fr) * 2005-11-04 2007-05-10 Zhejiang Hailisheng Pharmaceutical Limited Co. Montmorillonite modifiee, son procede de preparation et ses utilisations
FR2901360A1 (fr) 2006-05-16 2007-11-23 Horiba Abx Sas Soc Par Actions Dispositif de conditionnement pour analyse biologique
EP2025332A1 (fr) * 2007-08-13 2009-02-18 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Composition thérapeutique aromatisée à base d'argile

Also Published As

Publication number Publication date
CN101778622A (zh) 2010-07-14
CN104173371A (zh) 2014-12-03
TN2010000058A1 (fr) 2011-09-26
DK2194968T3 (da) 2013-09-02
GEP20125539B (en) 2012-05-25
EP2194968B1 (fr) 2013-06-19
PT2194968E (pt) 2013-07-25
KR20140133617A (ko) 2014-11-19
HK1143956A1 (en) 2011-01-21
US20100159013A1 (en) 2010-06-24
SA08290496B1 (ar) 2012-11-03
NO20100114L (no) 2010-03-10
US20140377354A1 (en) 2014-12-25
HUE029713T2 (en) 2017-03-28
CL2008002366A1 (es) 2009-05-29
EP2194968A1 (fr) 2010-06-16
EP2025332A1 (fr) 2009-02-18
BRPI0814979A2 (pt) 2015-02-03
HK1196271A1 (zh) 2014-12-12
JP5670189B2 (ja) 2015-02-18
ES2421379T3 (es) 2013-09-02
TW201509424A (zh) 2015-03-16
ES2582871T3 (es) 2016-09-15
AR067929A1 (es) 2009-10-28
PL2710998T3 (pl) 2016-11-30
WO2009056703A1 (fr) 2009-05-07
ME00975B (me) 2012-06-20
TWI519303B (zh) 2016-02-01
WO2009056703A8 (fr) 2010-03-04
CA2696062C (fr) 2017-09-05
EA201070257A1 (ru) 2010-06-30
TW200914034A (en) 2009-04-01
EA017118B1 (ru) 2012-09-28
JP2014208715A (ja) 2014-11-06
EP2710998A1 (fr) 2014-03-26
MX2010001533A (es) 2010-03-15
JP2010535852A (ja) 2010-11-25
UA97408C2 (ru) 2012-02-10
PL2194968T3 (pl) 2013-10-31
PT2710998T (pt) 2016-07-28
CA2696062A1 (fr) 2009-05-07
EP2710998B1 (fr) 2016-04-20
KR20100055460A (ko) 2010-05-26
US9056055B2 (en) 2015-06-16
TWI511734B (zh) 2015-12-11
KR101503957B1 (ko) 2015-03-18
PE20090939A1 (es) 2009-07-27
MA31678B1 (fr) 2010-09-01

Similar Documents

Publication Publication Date Title
AR114148A2 (es) Composición terapéutica saborizada basada en arcilla
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
UY29249A1 (es) Agentes citotóxicos que comprenden taxanos nuevos
CL2011001966A1 (es) Composicion farmaceutica que comprende derivados de glucopiranosil difenilmetano como inhibidor sglt-2; forma farmaceutica que comprende una composicion farmaceutica; procedimiento de preparacion y uso en el control glucemico.
CO6440531A2 (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
UY29250A1 (es) Agentes citotóxicos que comprenden nuevos taxanos modificados en c-2.-
HN2008000792A (es) Compuesto de cinamida biciclico
DE602005007488D1 (de) Zusammensetzung mit interkalierten funktionell aktiven organischen verbindungen
BRPI0808798A2 (pt) Fenoxifenilamidinas 3,5-dissubstituídas e seu uso como fungicidas
AR064830A1 (es) Composiciones para el cuidado oral que comprenden un extracto de hippophae
CL2008000610A1 (es) Composicion en forma de dosificacion transdermica o transmucosa que comprende una relacion en peso de buprenorfina a naloxona entre 2,1:1 y 8:1, util para el tratamiento del dolor.
CR11133A (es) Composicion biofertilizante
AR111471A2 (es) Composición de combinación sinérgica
PE20121538A1 (es) Combinaciones terapeuticas de teobromina y una antihistamina
MA32461B1 (fr) Dronedarone pour la prevention de cardioversion
BRPI0911573A2 (pt) preservativo com agente ativo localizado.
BRPI0906855A2 (pt) válvula sequencial e trator de perfuração.
BRPI0921011A2 (pt) métodos para provocar pelo menos um de um aumento no umedecimento oral e alívio de um sintoma associado com a hipossalivação , e aumento nos níveis de umedecimento oral, e, produto para cuidado oral
UY28812A1 (es) Agente parasiticida
BRPI0907700A2 (pt) Imidazopiridazinas como inibidores par1, produção das mesmas e uso como medicamentos
CL2007000554A1 (es) Metodo para diagnosticar matastasis en el nodulo linfatico de un carcinoma gastrico; y metodo para determinar o ajustar una terapia para un paciente con carcinoma gastrico.
CL2011000614A1 (es) Forma de dosificacion oral solida que comprende alisquireno solo o en combinacion con otro agente activo; proceso de preparacion; y uso en el tratamiento de enfermedades tales comohipertension, angina, ateroesclerosis, entre otras.
AR090486A1 (es) Golosina de tres capas con estabilidad temporal mejorada
BRPI0513495A (pt) salicilato de 4-hepten-2-ila e seu uso como ingrediente de fragráncia
FR2920926B1 (fr) Dephaseur actif integre.

Legal Events

Date Code Title Description
FB Suspension of granting procedure